Select date

May 2024
Mon Tue Wed Thu Fri Sat Sun

LancetGate: “Scientific Corona Lies” and Big Pharma Corruption. Hydroxychloroquine versus Gilead’s Remdesivir

14-7-2020 < SGT Report 26 894 words
 

by Prof Michel Chossudovsky, Global Research:



Minor updates and additions on July 6, 2020


Introduction


There is an ongoing battle to suppress Hydroxychloroquine (HCQ), a cheap and effective drug for the treatment of Covid-19. The campaign against HCQ is carried out through slanderous political statements, media smears, not to mention an authoritative peer reviewed “evaluation”  published on May 22nd by The Lancet, which was based on fake figures and test trials.



The study was allegedly based on data analysis of 96,032 patients hospitalized with COVID-19 between Dec 20, 2019, and April 14, 2020 from 671 hospitals Worldwide. The database had been fabricated. The objective was to kill the Hydroxychloroquine (HCQ) cure on behalf of Big Pharma.


While The Lancet article was retracted, the media casually blamed “a tiny US based company” named Surgisphere whose employees included “a sci-fi writer and adult content model” for spreading “flawed data” (Guardian). This Chicago based outfit was accused of having misled both the WHO and national governments, inciting them to ban HCQ. None of those trial tests actually took place.



While the blame was placed on Surgisphere, the unspoken truth (which neither the scientific community nor the media have acknowledged) is that the study was coordinated by Harvard professor Mandeep Mehra under the auspices of Brigham and Women’s Hospital (BWH) which is a partner of the Harvard Medical School.


When the scam was revealed, Dr. Mandeep Mehra who holds the Harvey Distinguished Chair of Medicine at  Brigham and Women’s Hospital apologized:



I have always performed my research in accordance with the highest ethical and professional guidelines. However, we can never forget the responsibility we have as researchers to scrupulously ensure that we rely on data sources that adhere to our high standards.


It is now clear to me that in my hope to contribute this research during a time of great need, I did not do enough to ensure that the data source was appropriate for this use. For that, and for all the disruptions – both directly and indirectly – I am truly sorry. (emphasis added)


Mandeep R. Mehra, MD, MSC  (official statement on BWH website)



But that “truly sorry” note was just the tip of the iceberg. Why?


Studies on Gilead Science’s Remdesivir and Hydroxychloroquine (HCQ) Were Conducted Simultaneously by Brigham and Women’s Hospital (BWH)


While The Lancet report (May 22, 2020) coordinated by Dr. Mandeep Mehra was intended “to kill” the legitimacy of HCQ as a cure of Covid-19, another important (related) study was being carried out (concurrently) at BWH pertaining to Remdesivir on behalf of Gilead Sciences Inc. Dr. Francisco Marty, a specialist in Infectious Disease and Associate Professor at Harvard Medical School was entrusted with coordination of the clinical trial tests of the antiviral medication Remdesivir under Brigham’s contract with Gilead Sciences Inc:







Brigham and Women’s Hospital began enrolling patients in two clinical trials for Gilead’s antiviral medication remdesivir. The Brigham is one of multiple clinical trial sites for a Gilead-initiated study of the drug in 600 participants with moderate coronavirus disease (COVID-19) and a Gilead-initiated study of 400 participants with severe COVID-19.








… If the results are promising, this could lead to FDA approval, and if they aren’t, it gives us critical information in the fight against COVID-19 and allows us to move on to other therapies.”



While Dr. Mandeep Mehra was not directly involved in the Gilead Remdesevir BWH study under the supervision of his colleague Dr. Francisco Marty, he nonetheless had contacts with Gilead Sciences Inc: “He participated in a conference sponsored by Gilead in early April 2020 as part of the Covid-19 debate” (France Soir, May 23, 2020)


What was the intent of his (failed) study? To undermine the legitimacy of Hydroxychloroquine?


According to France Soir, in a report published after The Lancet Retraction:



The often evasive answers produced by Dr Mandeep R. Mehra, … professor at Harvard Medical School, did not produce confidence, fueling doubt instead about the integrity of this retrospective study and its results. (France Soir, June 5, 2020)



Was Dr. Mandeep Mehra in conflict of interest? (That is a matter for BWH and the Harvard Medical School to decide upon).


Who are the Main Actors? 


Dr. Anthony Fauci, advisor to Donald Trump, portrayed as “America’s top infectious disease expert” has played a key role in smearing the HCQ cure which had been approved years earlier by the CDC as well as providing legitimacy to Gilead’s Remdesivir.


Dr. Fauci has been the head of the National Institute of Allergy and Infectious Diseases (NIAID) since the Reagan administration. He is known to act as a mouthpiece for Big Pharma.


Dr. Fauci launched Remdesivir in late June (see details below). According to Fauci, Remdesevir is the “corona wonder drug” developed by Gilead Science Inc. It’s a $1.6 billion dollar bonanza.


Gilead Sciences Inc: History


Gilead Sciences Inc is a Multibillion dollar bio-pharmaceutical company which is now involved in developing and marketing Remdesivir. Gilead has a long history. It has the backing of major investment conglomerates including the Vanguard Group and Capital Research & Management Co, among others. It has developed ties with the US Government.


Read More @ GlobalResearch.ca



Print